The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.

Kohei  Shitara

Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical

Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks

Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)

Mahmut  Gumus

Honoraria - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)

Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)

Research Funding - Amgen (Inst); MSD Oncology (Inst); Pfizer (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Pfizer

Filippo  Pietrantonio

Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda

Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda

Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)

Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation

Sara  Lonardi

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda

Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier

Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)

Christelle  De La Fouchardiere

Consulting or Advisory Role - Amgen; Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER; Takeda

Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER

Clélia  Coutzac

Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER

Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; SERVIER

Speakers' Bureau - Amgen; Merck Serono; SERVIER

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mundipharma; Sandoz; SERVIER

Jeroen  Dekervel

Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb Belgium; Eisai; Medtalks; MSD; Roche; Takeda

Speakers' Bureau - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Ipsen; Merck; MSD; Roche

Travel, Accommodations, Expenses - Amgen; Ipsen; Roche; SERVIER

Daniel  Hochhauser

Stock and Other Ownership Interests  - Moderna Therapeutics; Novartis; Roche

Lin  Shen

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited

Research Funding - BeiGene (Inst)

Wasat  Mansoor

Honoraria - Amgen; Astellas Pharma; BMS; BMS; Servier

Consulting or Advisory Role - Amgen; Amgen; BeiGene; BMS; Ipsen; MSD Oncology; SERVIER

Speakers' Bureau - BMS GmbH & Co. KG; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Lilly

Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Ipsen; SERVIER; SERVIER

Bo  Liu

No Relationships to Disclose

Lorenzo  Fornaro

Honoraria - BMS GmbH & Co. KG; Incyte; Lilly; MSD; SERVIER

Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Daiichi Sankyo; BeiGene; Incyte; Lilly; MSD; SERVIER; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS GmbH & Co. KG (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Incyte (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche (Inst)

Min-Hee  Ryu

Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical

Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)

Jeeyun  Lee

Consulting or Advisory Role - Amgen; AstraZeneca; Daichi Sankyo; Guardant Health AMEA; Immunoncia; Mirati Therapeutics; Trutino Biosciences

Research Funding - AstraZeneca; Merck Sharp & Dohme; Samsung Biopeis; Samsung Biopeis

Fabricio  Souza

Employment - Daiichi Sankyo / Merck

Stock and Other Ownership Interests  - Daiichi Sankyo / Merck

Lori  Jukofsky

Employment - Daiichi Sankyo Inc

Stock and Other Ownership Interests  - Daiichi Sankyo Inc

Travel, Accommodations, Expenses - Daiichi Sankyo Inc

Yumin  Zhao

Employment - Daiichi Sankyo, Inc; EQRx

Takahiro  Kamio

Employment - Daiichi Sankyo/Astra Zeneca

Aziz  Zaanan

Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Jazz Pharmaceuticals; Merck Serono; MSD; Pierre Fabre; Sanofi; SERVIER

Research Funding - Amgen

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Jazz Pharmaceuticals; Merck; MSD; Pierre Fabre; SERVIER

Eric  Van Cutsem

Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics